Charles Schwab Trust Co lessened its holdings in shares of Bristol-Myers Squibb (NYSE: BMY – Get Rating) by 22.3% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,702 shares of the biopharmaceutical company stock after selling 3,080 shares during the quarter. Charles Schwab Trust Co’s holdings in Bristol-Myers Squibb were worth $ 782,000 as of its most recent filing with the SEC.
Other institutional investors have also added to or reduced their stakes in the company. New England Professional Planning Group Inc. purchased a new stake in shares of Bristol-Myers Squibb during the 1st quarter worth approximately $ 220,000. Horan Securities Inc. acquired a new position in Bristol-Myers Squibb during the fourth quarter worth approximately $ 29,000. Steward Financial Group LLC acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $ 29,000. Guardian Wealth Management Inc. purchased a new position in shares of Bristol-Myers Squibb during the fourth quarter worth approximately $ 32,000. Finally, Consolidated Planning Corp acquired a new stake in shares of Bristol-Myers Squibb during the third quarter worth about $ 34,000. Institutional investors own 73.07% of the company stock.
Several research analysts have weighed in on BMY shares. Citigroup reiterated a “buy” rating and issued a $ 90.00 target price on shares of Bristol-Myers Squibb in a research note on Friday, June 3rd. Truist Financial upped their price objective on shares of Bristol-Myers Squibb from $ 76.00 to $ 81.00 in a research report on Monday, May 2nd. Morgan Stanley reduced their target price on shares of Bristol-Myers Squibb from $ 66.00 to $ 64.00 and set an “underweight” rating for the company in a research note on Wednesday, April 6th. Wells Fargo & Company increased their price target on shares of Bristol-Myers Squibb from $ 65.00 to $ 70.00 and gave the stock an “equal weight” rating in a report on Tuesday, May 17th. Finally, Guggenheim lifted their price objective on Bristol-Myers Squibb from $ 72.00 to $ 80.00 in a report on Monday, May 2nd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the company stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $ 74.27.
Shares of BMY stock opened at $ 77.69 on Friday. The stock has a fifty day moving average price of $ 75.93 and a 200 day moving average price of $ 69.97. The company has a debt-to-equity ratio of 1.18, a quick ratio of 1.23 and a current ratio of 1.32. The stock has a market cap of $ 165.41 billion, a PE ratio of 27.55, a P / E / G ratio of 1.62 and a beta of 0.49. Bristol-Myers Squibb has a 1 year low of $ 53.22 and a 1 year high of $ 78.61.
Bristol-Myers Squibb (NYSE: BMY – Get Rating) last released its quarterly earnings results on Friday, April 29th. The biopharmaceutical company reported $ 1.96 earnings per share (EPS) for the quarter, topping the estimate consensus of $ 1.92 by $ 0.04. Bristol-Myers Squibb had a return on equity of 48.37% and a net margin of 13.31%. The business had revenue of $ 11.65 billion during the quarter, compared to the consensus estimate of $ 11.34 billion. During the same quarter in the previous year, the company posted $ 1.74 EPS. The business’s revenue was up 5.2% on a year-over-year basis. As a group, equities research analysts predict that Bristol-Myers Squibb will post 7.56 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, August 1st. Shareholders of record on Friday, July 1st will be issued a $ 0.54 dividend. This represents a $ 2.16 annualized dividend and a dividend yield of 2.78%. The ex-dividend date of this dividend is Thursday, June 30th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 76.60%.
In related news, CEO Giovanni Caforio sold 30,000 shares of the company stock in a transaction that occurred on Monday, June 13th. The stock was sold at an average price of $ 74.04, for a total value of $ 2,221,200.00. Following the sale, the chief executive officer now owns 551,104 shares of the company stock, valued at approximately $ 40,803,740.16. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Sandra Leung sold 65,000 shares of the stock in a transaction on Monday, June 6th. The shares were sold at an average price of $ 74.89, for a total value of $ 4,867,850.00. Following the sale, the executive vice president now owns 308,627 shares in the company, valued at approximately $ 23,113,076.03. The disclosure for this sale can be found here. 0.09% of the stock is owned by corporate insiders.
Bristol-Myers Squibb Profile: (Get Rating)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke / systemic embolism in NVAF, and for the treatment of DVT / PE; Opdivo for anti-cancer indications; Pomalyst / Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE: BMY – Get Rating).
Receive News & Ratings for Bristol-Myers Squibb Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bristol-Myers Squibb and related companies with MarketBeat.com’s FREE daily email newsletter.